35Pharma
Part of GSK
CompanyCanada
35Pharma develops one asset, in phase 1 (HS235 in heart failure with preserved ejection fraction). Mostly protein or enzyme; based in Canada.
- 1
- Asset
- Furthest stage
- Phase 1
- 2
- Trials
- 0
- Signals
Pipeline
1Ligand trap that inhibits activin receptor signaling.
Phase 1, Protein or enzyme, heart failure with preserved ejection fraction, pulmonary arterial hypertension
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Similar companies6